AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
Phase 4
Completed
- Conditions
- HeartburnGastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT00637845
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: exenatide once weeklyDrug: sitagliptinDrug: pioglitazoneDrug: placebo tabletDrug: placebo once weekly
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00637273
- Locations
- 🇲🇽
Research Site, Toluca, Mexico
Study of AZD8931 in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT00637039
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Ph II Early BC Pre-Surgical Biologic Study
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00637026
ZAP, US. Zomig for Appropriate for Primary Care
Phase 4
Completed
- Conditions
- Migraine
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00637286
Gynecomastia Extension Study
Phase 3
Completed
- Conditions
- Gynecomastia
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00637182
Open Label Trial to Assess Iressa in Prostate Cancer Patients
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00635856
Open-Label Extension of Other SZ1839 (Iressa) Trials
Phase 3
Completed
- Conditions
- Cancer
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00635973
Second Line Breast Cancer Trial
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 588
- Registration Number
- NCT00635713
Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer
- Conditions
- Adenocarcinoma of the Prostate
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2008-06-11
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00636259
© Copyright 2025. All Rights Reserved by MedPath